INTRODUCTION
Focal adhesion kinase (FAK) is a non-receptor cytoplasmic tyrosine kinase that is encoded by PTK2 (chromosome 8q24.3). FAK is involved in many cellular processes through its role in integrin and growth factor signaling, with activation of FAK inducing recruitment of several SH2-domain-and SH3-domain-containing proteins that mediate signaling Abbreviations: EFS T/C, ratio of event-free survival treated to control; FAK, focal adhesion kinase; MPM, malignant pleural mesothelioma; (NOD)/scid −/− , non-obese diabetic/severe combined immune deficient; PPTP, Pediatric Preclinical Testing Program to downstream pathways. 1 A role for FAK in cancer has been suspected since it was described as a protein with increased tyrosine phosphorylation in viral Src-transformed chicken embryo cells. [2] [3] [4] Subsequent research has provided evidence for a role of FAK in promotion of cancer through effects on cell survival, angiogenesis, migration, proliferation, epithelial-mesenchymal transformation, invasion, and stem cell maintenance. 5 Several small molecule inhibitors of FAK have entered clinical development, including defactinib (VS-6063, PF-04554878), VS-4718, and GSK2256098. 5 Here we report the in vitro and in vivo activity of VS-4718 against PPTP cell lines and xenograft models.
MATERIALS AND METHODS

In vitro testing
In vitro testing was performed using DIMSCAN and cells were incubated in the presence of VS-4718 for 96 hours at concentrations from 1.0 nM to 10 M and analyzed as previously described. 7,8
In vivo tumor growth inhibition studies
Procedures for propagation of xenografts in CB17SC scid −/− for solid tumors, BALB/c nu/nu mice for glioma models, 9 and NOD/scid −/− mice in leukemia models have been described previously. 10 All mice were maintained under barrier conditions, and experiments were conducted using protocols and conditions approved by the institutional animal care and use committee of the appropriate consortium member. An indepth description of the analysis methods is included in Supplementary Appendix S1. Statistical methods for analysis have been described previously. 9 a EFS T/C value is defined by the ratio of the median time to event of the treatment group and the median time to event of the respective control group. High activity requires: (a) an EFS T/C > 2; (b) a significant difference in EFS distributions; and (c) a net reduction in median tumor volume for animals in the treated group at the end of treatment as compared to at treatment initiation. Intermediate activity demonstrates criteria (a) and (b) above, but not having a net reduction in median tumor volume for treated animals at the end of the study. Low activity demonstrates EFS T/C < 2. 3 Objective response measures are described in detail in the Response Definitions in Supplementary Appendix S1. PD1 = progressive disease with EFS T/C ≤ 1.5, and PD2 = progressive disease with EFS T/C > 1. 
Drugs and formulation
RESULTS
VS-4718 in vitro testing
VS-4718 was tested against the PPTP's in vitro
VS-4718 in vivo testing
VS-4718 was well tolerated, with only a 1.2% mortality rate (5/427) in the treated groups, the same as that observed for control animals.
Each of 44 tested xenograft models was considered evaluable for efficacy. Complete details of testing are provided in Supplementary Table   S1 . VS-4718 induced significant differences in an event-free survival (EFS) distribution compared with control in 18 of 36 (50%) of the evaluable solid tumor xenografts and in 0 of 8 (0%) of the evaluable ALL xenografts, including the Ph + ALL xenograft, ALL-4 ( Table 2) . Significant differences in the EFS distribution were most commonly observed 
DISCUSSION
VS-4718 inhibits FAK phosphorylation at Y397 in cellular assays with an IC 50 in the 100 nM range, 6 and it also reduces the proportion of can- A recent publication highlighted the potential utility for FAK inhibition against ALL that exhibits loss of Ikaros function, 14 a finding that is particularly common in Ph + ALL expressing the BCR-ABL1 fusion gene. 15 Joshi et al. 14 
